ANGELA MARTS: Open Payments
NPI 1730519091 · REISTERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,297 in 65 payments from 17 companies in 2025. Trend: 2023 $980 · 2024 $1,232 · 2025 $1,297
Food & beverage: $1,297
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $243 |
| Novo Nordisk Inc | 9 | $204 |
| AstraZeneca Pharmaceuticals LP | 11 | $199 |
| PFIZER INC. | 6 | $121 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $75 |
| Lilly USA, LLC | 4 | $68 |
| Amgen Inc. | 3 | $62 |
| Merck Sharp & Dohme LLC | 2 | $54 |
| Paratek Pharmaceuticals, Inc. | 3 | $48 |
| Astellas Pharma US Inc | 2 | $47 |
Products named: VRAYLAR, Ozempic, AIRSUPRA, UBRELVY, NURTEC ODT, Rybelsus, XIFAXAN, FARXIGA.
Industry payments across MD — which companies pay providers there.
